Dr. Sutphin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
92 W Miller St
Orlando, FL 32806Phone+1 321-230-8138Fax+1 407-337-0137
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 2004 - 2007
- University of Florida (Orlando)Residency, Pediatrics, 2001 - 2004
- Marshall University Joan C. Edwards School of MedicineClass of 2001
Certifications & Licensure
- FL State Medical License 2007 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients Start of enrollment: 2010 Jan 01
- Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2011 Jul 18
Publications & Presentations
PubMed
- Combination Chemotherapy in Severe Pulmonary Vein Stenosis-A Case Series.Gabriel Krivenko, Karen Iacono, David Nykanen, Robyn Keen, Robert Sutphin
Children. 2023-02-11 - 5 citationsCombination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cellsShruti Patil, Umesh T. Sankpal, Myrna Hurtado, W. Paul Bowman, Jeffrey Murray
Gene. 2019-07-15 - 5 citationsCombination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation.Sagar Shelake, Don Eslin, Robert M. Sutphin, Umesh T Sankpal PhD, Anmol Wadwani
International Journal of Developmental Neuroscience. 2015-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: